Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration (Q37980818)

26 August 2017

title

Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration (English)

1 reference

26 August 2017

1 reference

Peter K Kaiser

2

0 references

author name string

Matthew Ohr

series ordinal

1

1 reference

26 August 2017

language of work or name

English

0 references

publication date

3 February 2012

1 reference

Expert Opinion on Pharmacotherapy

26 August 2017

published in

1 reference

26 August 2017

volume

13

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

585-591

1 reference

Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy an

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

Ranibizumab for the treatment of neovascular age-related macular degeneration: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

Predicted biological activity of intravitreal VEGF Trap.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658368

10.1517/14656566.2012.658368

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference